Results 151 to 160 of about 359,117 (344)

A phenomap of TTR amyloidosis to aid diagnostic screening

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1113-1118, April 2025.
Abstract Cardiac amyloidosis due to transthyretin (ATTR) remains an underdiagnosed cause of cardiomyopathy. As awareness of the disease grows and referrals for ATTR increase, clinicians are likely to encounter more atypical forms of the condition in clinical practice.
Alexios S. Antonopoulos   +4 more
wiley   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad   +9 more
wiley   +1 more source

Studies in clinical shock and hypotension [PDF]

open access: bronze, 1969
Jay N. Cohn   +2 more
openalex   +1 more source

Pulmonary congestion relief by adding dapagliflozin to intravenous loop diuretic in acute heart failure patients

open access: yesESC Heart Failure, EarlyView.
Abstract Aims We aim to assess the efficacy of congestion relief and safety associated with adding SGLT2i (viz., dapagliflozin 10 mg) to intravenous loop diuretics within 24 h of hospital presentation in patients with acute heart failure (AHF). Methods and results A single‐centre open‐label clinical research study enrolled 98 patients admitted with an ...
Daniela Mocan   +7 more
wiley   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

open access: yes, 2022
Hepatology, EarlyView.
Robert J. Fontana   +6 more
wiley   +1 more source

Efficacy of ambulatory intravenous diuresis for chronic heart failure patients: Insights from the DEA‐HF trial

open access: yesESC Heart Failure, EarlyView.
Graphical presentation of the study design, main results and conclusion. Abbreviations: Y/O = year old; HFpEF = heart failure with preserved ejection fraction; Kg = kilograms; NYHA = New York Heart Association; ACE = angiotensin‐converting enzyme; ARB = angiotensin receptor blockers; ARNI = angiotensin receptor‐neprilysin inhibitor; SGLT2i = sodium ...
Amit Gruber   +14 more
wiley   +1 more source

Patient‐specific modifiers of survival benefit in cardiac resynchronization therapy ‐ A multicentre interaction analysis

open access: yesESC Heart Failure, EarlyView.
Abstract Background Cardiac resynchronization therapy (CRT) is a key intervention for patients with heart failure. The choice between a CRT with defibrillator therapy (CRT‐D) and a CRT with pacemaker (CRT‐P) is influenced by individual clinical characteristics.
Bert Vandenberk   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy